The problem with the new stricter rules is that fewer manufacturers will meet all the new criteria. The ones that do will however have a much bigger slice of the market.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025